Status:
RECRUITING
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Lead Sponsor:
Bayer
Conditions:
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make u...
Eligibility Criteria
Inclusion
- Adult participants of all genders (≥18 years old)
- Diagnosis of CKD associated with T2D based on assessment by physician.
- Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
- Decision to initiate treatment with finerenone must be made before ICF is signed.
- Signed informed consent
Exclusion
- Participation in an investigational trial at any time during the course of this study
- Contra-indications according to the local label.
Key Trial Info
Start Date :
June 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2026
Estimated Enrollment :
4500 Patients enrolled
Trial Details
Trial ID
NCT05348733
Start Date
June 13 2022
End Date
December 15 2026
Last Update
January 6 2026
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrology Consultants LLC
Huntsville, Alabama, United States, 35805
2
AKDHC Medical Research Servies LLC
Phoenix, Arizona, United States, 85016
3
Harrisburg Family Medical Center
Harrisburg, Arkansas, United States, 72432
4
Kidney Disease Medical Group
Glendale, California, United States, 91206